Biopredic International

What Biopredic International does

Biopredic International is a French privately-held biotechnology company founded in the 1990s and headquartered in Saint-Grégoire (Rennes metropolitan area, Brittany). It operates as the biological-assay arm of the Wepredic biotech group, which also encompasses Eurosafe (safety and bioavailability assessment services) and Starlight (chemical design and synthesis). Biopredic manufactures and distributes proprietary in vitro biological assay systems built around its flagship hepatic cell lines, HepaRG® and HepaSH™, which are used by customers to model human liver metabolism, hepatotoxicity, and drug-drug interactions. The company also sells supporting reference compounds (e.g., Prazosin as an OCT1 inhibitor, Cholecystokinin 8 as an OATP1B3 substrate) and maintains a scientific publication library for each cell line to support customer validation and regulatory submissions.

The company's business model combines direct e-commerce sales of small-ticket research products (priced in euros at €45-€95 per unit, with 48-hour global delivery) with enterprise sales to pharmaceutical, cosmetics, and chemical industry customers. Named enterprise users include Sephora, Nuxe, Pierre Fabre, and Yves Rocher in cosmetics, alongside unnamed pharmaceutical and industrial compound customers. Distribution runs through Biopredic's own online storefront on the Wepredic group website as well as direct enterprise engagement, with participation in industry conferences such as SOT (Society of Toxicology) and SSX India used to drive awareness and lead generation. Revenue is not publicly disclosed; the company does not have institutional funding rounds on record and remains a privately-held subsidiary within the Wepredic group, currently led by CEO Christophe Chesne.

Name

Biopredic International

Legal name

Biopredic International

Website

https://biopredic.com

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

11–50 employees

Short description

Biopredic International is a French biotech subsidiary of the Wepredic group that manufactures proprietary in vitro biological assay systems, including the HepaRG® and HepaSH™ hepatic cell lines, for pharmaceutical, cosmetics, and chemical industry customers conducting drug metabolism and safety assessment studies.

Ownership category

akta.pro rank

Product category

In Vitro Toxicology & Safety Assessment Reagents

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Pharmaceutical and Medicine Manufacturing (32541)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

In Vitro Toxicology (Cell-based/Organ-on-chip) (HLAGAFAJ)

akta.pro secondary industry

DMPK / ADME & Bioanalysis (HLAGAFAC)

Keywords

• In vitro toxicology testing
• Biological assay systems
• Hepatocyte cell lines
• Drug metabolism research
• Cosmetics safety assessment

Headquarters

HQ city

Saint-grégoire

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Assay Systems and Cell Products Sales: Direct sales of proprietary biological assay systems including HepaRG® and HepaSH™ cell products, as well as related biochemical reagents (OCT1 inhibitors, OATP1B3 substrates). Sold through e-commerce platform with 48h delivery to customers worldwide.
2. Safety Assessment Services: Through affiliated company Eurosafe, provides safety and bioavailability assessment services for drugs, cosmetics, and industrial compounds using proprietary cell systems and assay platforms.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Biopredic International manufactures and markets proprietary biological assay systems used to assess the fate and safety of drugs, cosmetics, and industrial compounds. Its portfolio centers on the HepaRG® hepatic cell line and HepaSH™ hepatocyte system for in vitro drug metabolism, hepatotoxicity, and drug-drug interaction studies, supplemented by reference compounds (e.g., Prazosin as an OCT1 inhibitor, Cholecystokinin 8 as an OATP1B3 substrate) and complemented by safety/bioavailability assessment services delivered through affiliated Eurosafe.

Product overview

Biopredic International is a division of the Wepredic biotech group that manufactures and markets biological assay systems. The company's portfolio includes the HepaRG® and HepaSH™ cell-based products for liver toxicity testing and drug metabolism studies, along with reference compounds such as Prazosin (OCT1 inhibitor) and Cholecystokinin 8 (OATP1B3 substrate) used in drug-drug interaction testing. The products serve pharmaceutical, cosmetics, and chemical industries for safety assessment of drugs, cosmetics, and industrial compounds.

Differentiator

Problem solved

Functional benefit

Brands

• Biopredic Advancells: Biological assay systems brand with dedicated website at biopredicadvancells.com

Products and services

• HepaRG® Proprietary hepatocyte cell line used for drug metabolism studies, hepatotoxicity testing, and safety assessment. Maintains liver-specific functions in culture and serves as a gold standard for in vitro toxicology applications, supported by an extensive publication database.
• HepaSH™ Proprietary hepatocyte cell system used for studying hepatic drug interactions and compound safety profiling, including xenobiotics metabolism and safety evaluation.
• Prazosin OCT1 inhibitor reference compound used in drug-drug interaction studies and hepatic transporter assays. Priced at €45.00 incl. tax with 48h delivery.
• Cholecystokinin 8 OATP1B3 substrate reference compound used in transporter inhibition assays. Priced at €95.00 incl. tax with 48h delivery.
• Safety and Bioavailability Assessment Services (via Eurosafe) Safety and bioavailability assessment services for drugs, cosmetics, and industrial compounds, using Biopredic's proprietary cell systems and assay platforms. Sold on a professional-services basis to pharmaceutical, cosmetics, and chemical industry customers.

Named customers4 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Wepredic GroupcoreStrategic or Co-development PartnerBiopredic International operates as a key subsidiary within the Wepredic biotech group, which includes Wepredic (biological and chemical systems expertise), Eurosafe (safety and bioavailability services), and Starlight (chemical design and synthesis). This integrated structure allows for comprehensive solutions from chemical design through safety assessment.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Lonza: Swiss global contract manufacturer and life sciences tools provider offering primary cells, hepatic cell models, and cell-based in vitro toxicology services. Lonza is named alongside Biopredic in the primary cells market and represents the large-scale incumbent Biopredic competes against.
• Thermo Fisher Scientific: The world's largest life sciences tools company, offering Gibco primary hepatocytes, in vitro toxicology reagents, and contract research services. Thermo Fisher is explicitly named alongside Biopredic in the primary cells market and competes broadly across the same customer base.
• Eurofins Scientific: International testing services group offering in vitro toxicology, cosmetics safety testing, and chemical REACH compliance services. Eurofins competes with Eurosafe's service arm in the cosmetics and chemicals testing verticals.
• Merck KGaA: German science and technology company operating the Life Science division (MilliporeSigma) which produces primary cells, hepatocyte products, and toxicology testing reagents. Merck KGaA is explicitly named alongside Biopredic in the primary cells market.
• Charles River Laboratories: Global CRO offering preclinical safety assessment, in vitro toxicology services, and research models including hepatic systems. Charles River is a broad incumbent with overlapping cell-based safety assessment services relevant to Biopredic's customer base.

Direct peers

• Sekisui Xenotech: Specialized provider of hepatic cell products, hepatocyte transport and metabolism assays, and in vitro drug-drug interaction tools. Sekisui Xenotech is a direct competitor in the hepatocyte-focused in vitro toxicology reagent space.
• Inotiv: US-based preclinical CRO and research models provider offering in vitro toxicology services and cell-based safety assessment for pharmaceutical clients. Inotiv directly competes in the in vitro safety assessment services market.
• Cyprotex: UK/EU-based contract research organization specializing in in vitro ADME, DMPK, and toxicology services for pharmaceutical and cosmetics clients. Cyprotex is a direct comparable to Biopredic/Eurosafe's in vitro safety assessment services and HepaRG-based assays.
• BioIVT: US-based supplier of human primary hepatocytes, cell-based assay products, and in vitro toxicology research tools. BioIVT directly competes with Biopredic in the hepatic cell line and in vitro toxicology product market.

Emerging players

• Cellartis (Takara Bio): Provider of iPSC-derived hepatocyte products and cell-based in vitro toxicology platforms. Cellartis represents an emerging alternative cell-based technology that competes with HepaRG for next-generation toxicology applications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biopredic International